Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results. [electronic resource]
Producer: 20141113Description: 269 p. digitalISSN:- 1471-2334
- Adolescent
- Adult
- Aged
- Alkynes
- Anti-HIV Agents -- therapeutic use
- Benzoxazines -- therapeutic use
- Biomarkers -- blood
- C-Reactive Protein -- metabolism
- Carbamates -- therapeutic use
- Cyclopropanes
- Dideoxynucleosides -- therapeutic use
- Drug Combinations
- Female
- Fibrin Fibrinogen Degradation Products -- metabolism
- Fibrinogen -- metabolism
- Furans
- HIV Infections -- blood
- Humans
- Interleukin-6 -- blood
- Lamivudine -- therapeutic use
- Male
- Middle Aged
- Organophosphates -- therapeutic use
- Plasminogen -- metabolism
- Prospective Studies
- Ritonavir -- therapeutic use
- Sulfonamides -- therapeutic use
- Vascular Cell Adhesion Molecule-1 -- blood
- Young Adult
No physical items for this record
Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.